FR16C0016I1 - - Google Patents

Info

Publication number
FR16C0016I1
FR16C0016I1 FR16C0016C FR16C0016I1 FR 16C0016 I1 FR16C0016 I1 FR 16C0016I1 FR 16C0016 C FR16C0016 C FR 16C0016C FR 16C0016 I1 FR16C0016 I1 FR 16C0016I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR16C0016I1 publication Critical patent/FR16C0016I1/fr
Application granted granted Critical
Publication of FR16C0016I2 publication Critical patent/FR16C0016I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides
FR16C0016C 2000-03-10 2016-04-29 MODIFIED FACTOR VIII Active FR16C0016I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/523,656 US6458563B1 (en) 1996-06-26 2000-03-10 Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (en) 2000-03-10 2001-02-16 Modified factor viii

Publications (2)

Publication Number Publication Date
FR16C0016I1 true FR16C0016I1 (en) 2016-04-29
FR16C0016I2 FR16C0016I2 (en) 2018-11-02

Family

ID=24085870

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0016C Active FR16C0016I2 (en) 2000-03-10 2016-04-29 MODIFIED FACTOR VIII

Country Status (36)

Country Link
US (3) US6458563B1 (en)
EP (1) EP1280540B1 (en)
JP (1) JP4044337B2 (en)
KR (1) KR100485525B1 (en)
CN (1) CN1191360C (en)
AT (1) ATE391512T1 (en)
AU (2) AU2001238416B2 (en)
BE (1) BE2016C024I2 (en)
BR (2) BRPI0109131B8 (en)
CA (1) CA2400295C (en)
CY (2) CY1108179T1 (en)
CZ (1) CZ298250B6 (en)
DE (1) DE60133541T2 (en)
DK (1) DK1280540T3 (en)
EE (1) EE05075B1 (en)
ES (1) ES2304379T3 (en)
FR (1) FR16C0016I2 (en)
HK (1) HK1051004A1 (en)
HU (2) HU227804B1 (en)
IL (2) IL151371A0 (en)
LT (1) LTC1280540I2 (en)
LU (1) LU93049I2 (en)
ME (1) MEP8209A (en)
MX (1) MXPA02008798A (en)
NL (1) NL300808I2 (en)
NO (2) NO331935B1 (en)
NZ (1) NZ520799A (en)
PL (1) PL202936B1 (en)
PT (1) PT1280540E (en)
RS (1) RS50364B (en)
RU (1) RU2285724C2 (en)
SI (1) SI1280540T1 (en)
SK (1) SK286205B6 (en)
UA (1) UA75064C2 (en)
WO (1) WO2001068109A1 (en)
ZA (1) ZA200206810B (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
WO2002060951A2 (en) * 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
CA2461443C (en) * 2001-10-05 2011-07-12 Emory University Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
MXPA04005079A (en) * 2001-11-30 2004-08-19 Univ Emory Factor viii c2 domain variants.
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7709224B2 (en) * 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
PL1636261T3 (en) * 2003-06-26 2007-12-31 Merck Patent Gmbh Thrombopoietin proteins with improved properties
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
ATE463572T1 (en) * 2003-12-03 2010-04-15 Univ Rochester RECOMBINANT FACTOR VIII WITH INCREASED SPECIFIC ACTIVITY
DK1750733T3 (en) * 2004-05-03 2014-01-20 Univ Emory PROCEDURE FOR SUBMITTING PIG-B DOMAIN WITHOUT VVIII
WO2005123928A1 (en) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production of human coagulation factor viii from plant cells and whole plants
PL2371856T3 (en) * 2004-11-12 2022-08-22 Bayer Healthcare Llc Site-directed modification of FVIII
US20100256062A1 (en) * 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090215025A1 (en) 2005-12-07 2009-08-27 Technische Universitat Munchen Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
CA2649199C (en) * 2006-04-11 2015-01-20 Csl Behring Gmbh Method of increasing the in vivo recovery of therapeutic polypeptides
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP3231440A1 (en) * 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
FR2913020B1 (en) * 2007-02-23 2012-11-23 Biomethodes NEW VIII FACTORS FOR THE TREATMENT OF TYPE A HEMOPHILS
EP1988101A1 (en) * 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
RU2531493C2 (en) 2007-11-01 2014-10-20 Юниверсити Оф Рочестер Recombinant factor viii, possessing higher stability
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
MX2011008094A (en) 2009-02-03 2012-02-13 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same.
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
CA2764872C (en) 2009-06-09 2018-07-24 Prolong Pharmaceuticals, LLC Hemoglobin compositions
EP2498803A4 (en) * 2009-11-13 2013-05-15 Puget Sound Blood Ct Factor viii t cell epitope variants having reduced immunogenicity
EA025416B1 (en) 2009-12-06 2016-12-30 Байоджен Хемофилия Инк. Method for preventing or treating bleeding episodes using a long-acting factor viii chimeric polypeptide
US20110177107A1 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
HUE044419T2 (en) 2010-07-09 2019-10-28 Bioverativ Therapeutics Inc Processable single chain molecules and polypeptides made using same
EP2635297B1 (en) 2010-11-05 2019-02-27 Baxalta GmbH A new variant of antihemophilic factor viii having increased specific activity
JP2014504870A (en) * 2011-01-05 2014-02-27 エクスプレッション セラピューティクス， エルエルシー High-yield suspension cell line, system, and method for producing the same
SI2717898T1 (en) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
RS58578B1 (en) 2011-07-08 2019-05-31 Bioverativ Therapeutics Inc Factor viii chimeric and hybrid polypeptides, and methods of use thereof
EP2737311B1 (en) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
CN102277379B (en) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 Expression vector for expressing coagulation factor VIII and application thereof
SG10201610193RA (en) 2012-01-12 2017-01-27 Biogen Ma Inc Chimeric factor viii polypeptides and uses thereof
EA029560B1 (en) 2012-01-12 2018-04-30 Байоджен Эмэй Инк. Use of chimeric blood coagulation factor for reducing inhibitory immune response in a subject
HUE046848T2 (en) 2012-02-15 2020-03-30 Bioverativ Therapeutics Inc Factor viii compositions and methods of making and using same
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
WO2014011819A2 (en) 2012-07-11 2014-01-16 Amunix Operating Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
BR112015013311A2 (en) 2012-12-07 2017-11-14 Haplomics Inc tolerance induction and factor 8 mutation repair
EP4223772A3 (en) 2013-02-15 2023-10-18 Bioverativ Therapeutics Inc. Optimized factor viii gene
LT2968477T (en) 2013-03-15 2020-03-10 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
AU2014339034A1 (en) 2013-10-22 2016-05-19 Dbv Technologies Method of treating haemophilia by inducing tolerance to blood factors
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
LT3091997T (en) 2014-01-10 2022-08-25 Bioverativ Therapeutics Inc. Factor viii chimeric proteins and uses thereof
KR102567586B1 (en) 2014-02-04 2023-08-16 바이오젠 엠에이 인코포레이티드 Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CA2940127A1 (en) * 2014-02-19 2015-08-27 Bloodworks Factor viii b cell epitope variants having reduced immunogenicity
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
MA40864A (en) 2014-10-31 2017-09-05 Biogen Ma Inc HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
PE20231949A1 (en) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTS OF FACTOR VIII REDUCED WITH CpG, COMPOSITIONS AND METHODS AND USES FOR THE TREATMENT OF HEMOSTASY DISORDERS
CN108884145B (en) 2015-11-13 2023-08-22 武田药品工业株式会社 Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
KR102404550B1 (en) 2015-11-13 2022-05-31 다케다 야쿠힌 고교 가부시키가이샤 Viral vector encoding recombinant FVIII variant with increased expression for gene therapy of hemophilia A
CN116218863A (en) 2016-02-01 2023-06-06 比奥贝拉蒂治疗公司 Optimized factor VIII genes
JP6877469B2 (en) 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Chimeric proteins, including FVIII and VWF factors, and their use
EP3548066A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
EP3548063A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CA3063204A1 (en) * 2017-05-09 2018-11-15 Emory University Clotting factor variants and their use
KR20200035130A (en) 2017-08-09 2020-04-01 바이오버라티브 테라퓨틱스 인크. Nucleic acid molecules and uses thereof
AU2019215063A1 (en) 2018-02-01 2020-09-03 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing Factor VIII
CA3096038A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
US20190375822A1 (en) 2018-05-18 2019-12-12 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
KR20210034013A (en) 2018-07-16 2021-03-29 박스알타 인코퍼레이티드 Genetic treatment of hemophilia using viral vectors encoding recombinant FVIII variants with increased expression
CA3108799A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
TW202039546A (en) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
US20220233650A1 (en) 2019-06-19 2022-07-28 Bioverativ Therapeutics Inc. Recombinant factor viii-fc for treating hemophilia and low bone mineral density
EP3986481A2 (en) 2019-06-20 2022-04-27 Takeda Pharmaceutical Company Limited Method of treatment with viral-based gene therapy
EP4073106A2 (en) 2019-12-12 2022-10-19 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
TW202246505A (en) * 2021-03-05 2022-12-01 俄羅斯聯邦商亞那拜恩有限公司 Codon-optimized nucleic acid that encodes coagulation factor ix protein, and use thereof
WO2022212162A1 (en) * 2021-03-31 2022-10-06 Haemonetics Corporation Hemostasis measurement device quality control formulations
WO2022264040A1 (en) 2021-06-14 2022-12-22 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
IL310997A (en) 2021-08-23 2024-04-01 Bioverativ Therapeutics Inc Optimized factor viii genes
CA3232988A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
US4868112A (en) * 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
JPH0387173A (en) 1987-09-10 1991-04-11 Teijin Ltd Preparation of human active natural type factor viii c and transformant using the same
DK162233C (en) 1989-11-09 1992-03-16 Novo Nordisk As PROCEDURE FOR INSULATING FACTOR VIII FROM BLOOD PLASMA AND PHARMACEUTICAL PREPARATION CONTAINING THE ASSOCIATED PHATAR VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
WO1997003191A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
WO2002024723A1 (en) * 2000-09-19 2002-03-28 Emory University Modified factor viii
MXPA04005079A (en) * 2001-11-30 2004-08-19 Univ Emory Factor viii c2 domain variants.
US7105745B2 (en) * 2002-12-31 2006-09-12 Thomas & Betts International, Inc. Water resistant electrical floor box cover assembly

Also Published As

Publication number Publication date
KR20020081426A (en) 2002-10-26
FR16C0016I2 (en) 2018-11-02
UA75064C2 (en) 2006-03-15
AU2001238416B2 (en) 2004-09-02
RS50364B (en) 2009-11-10
NO331935B1 (en) 2012-05-07
HUS1600020I1 (en) 2016-06-28
CA2400295A1 (en) 2001-09-20
ATE391512T1 (en) 2008-04-15
EP1280540A4 (en) 2004-11-03
CN1191360C (en) 2005-03-02
NL300808I1 (en) 2016-05-18
BR122013026957A2 (en) 2004-12-07
CY2016011I1 (en) 2016-10-05
NO20024296D0 (en) 2002-09-09
RU2285724C2 (en) 2006-10-20
CY1108179T1 (en) 2014-02-12
SK286205B6 (en) 2008-05-06
AU3841601A (en) 2001-09-24
US20030068785A1 (en) 2003-04-10
PL359672A1 (en) 2004-09-06
EE05075B1 (en) 2008-10-15
HU227804B1 (en) 2012-03-28
NZ520799A (en) 2004-06-25
CA2400295C (en) 2012-01-10
BR0109131A (en) 2004-12-07
BRPI0109131B1 (en) 2020-08-25
CZ20023346A3 (en) 2003-01-15
PL202936B1 (en) 2009-08-31
LTC1280540I2 (en) 2020-05-25
US7122634B2 (en) 2006-10-17
CZ298250B6 (en) 2007-08-01
NO20024296L (en) 2002-11-08
HUP0300586A3 (en) 2006-11-28
DE60133541D1 (en) 2008-05-21
NO2016007I1 (en) 2016-05-10
JP4044337B2 (en) 2008-02-06
MXPA02008798A (en) 2003-04-25
DK1280540T3 (en) 2008-07-14
IL151371A0 (en) 2003-04-10
SI1280540T1 (en) 2008-08-31
HUP0300586A2 (en) 2003-06-28
WO2001068109A1 (en) 2001-09-20
DE60133541T2 (en) 2009-05-07
BE2016C024I2 (en) 2020-01-30
KR100485525B1 (en) 2005-04-28
US20050079584A1 (en) 2005-04-14
ZA200206810B (en) 2003-11-26
US6458563B1 (en) 2002-10-01
ME00601B (en) 2011-12-20
CN1416348A (en) 2003-05-07
IL151371A (en) 2010-12-30
EP1280540A1 (en) 2003-02-05
JP2003526358A (en) 2003-09-09
US7012132B2 (en) 2006-03-14
SK14392002A3 (en) 2003-06-03
ES2304379T3 (en) 2008-10-16
LU93049I2 (en) 2016-06-27
BRPI0109131B8 (en) 2021-07-06
MEP8209A (en) 2011-12-20
NL300808I2 (en) 2020-12-21
CY2016011I2 (en) 2016-10-05
NO2016007I2 (en) 2016-05-10
RU2002124123A (en) 2004-03-27
BR122013026957A8 (en) 2017-02-21
YU68002A (en) 2005-11-28
HK1051004A1 (en) 2003-07-18
EE200200510A (en) 2004-02-16
EP1280540B1 (en) 2008-04-09
PT1280540E (en) 2008-06-09

Similar Documents

Publication Publication Date Title
FR16C0016I1 (en)
BE2015C062I2 (en)
BE2014C009I2 (en)
DE60132457D1 (en)
BE2012C016I2 (en)
BE2010C018I2 (en)
BRPI0113085B8 (en)
BRPI0112928B8 (en)
JP2001216766A5 (en)
JP2003513544A5 (en)
JP2003518266A5 (en)
JP2001132727A5 (en)
JP2002093576A5 (en)
IN2002CH01637A (en)
IN192890B (en)
JP2001212290A5 (en)
JP2001215714A5 (en)
DE60140740D1 (en)
DE60135245D1 (en)
DE60133735D1 (en)
DE60041954D1 (en)
JP2001250981A5 (en)
BR0112866A2 (en)
KR100399514B1 (en)
BY5768C1 (en)